DTC
AXSM icon

Deep Track Capital’s Axsome Therapeutics AXSM Stock Holding History

Deep Track Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200,000
Closed -$18M – 68
2024
Q3 		$18M Buy
+200,000
New +$17.5M 0.57% 47

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Deep Track Capital's AXSM Position: Q2 2026 in Review

Deep Track Capital reduced its Axsome Therapeutics (AXSM) stake by 36% in Q2 2026, selling an estimated $86.7M and leaving 700,000 shares worth $171M. The position accounts for 2.49% of the portfolio, ranked #18.

Deep Track Capital first reported a position in AXSM in Q2 2023 and has held it in 11 quarters since. The position peaked at $210M in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Deep Track Capital held 700,000 shares of Axsome Therapeutics worth $171M as of Q2 2026.
  • Deep Track Capital sold 400,000 Axsome Therapeutics shares in Q2 2026, an estimated $86.7M.
  • Axsome Therapeutics made up 2.49% of Deep Track Capital's portfolio in Q2 2026, its #18 holding.
  • Deep Track Capital first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Deep Track Capital's Axsome Therapeutics position peaked at $210M in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.